SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients

Delattre, Émilie; Guillot, Xavier; Godfrin-Valnet, Marie; Prati, Clément; Wendling, Daniel

doi:10.1016/j.jbspin.2014.01.017

Cited by 25 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic or intra-articular corticosteroids may have positive effects, but their use is limited due to side effects and limited long-term efficacy [ 70 , 71 ]. Bisphosphonates are used regularly, especially if the spine is affected [ 40 , 72 ]. A not randomized study recently showed significant improvement of symptoms in response to treatment with pamidronate for spinal bone marrow edema, leading to the authors’ recommendation to use pamidronate as first-line treatment especially in cases with spinal involvement [ 73 ].…”

Section: Treatment Monitoring and Treat-to-target Protocolsmentioning

confidence: 99%

New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO

Hedrich

Morbach

Reiser³

et al. 2020

Curr Rheumatol Rep

View full text Add to dashboard Cite

Purpose of Review To describe in detail the clinical synopsis and pathophysiology of chronic non-bacterial osteomyelitis and SAPHO syndrome. Recent Findings Chronic non-bacterial osteomyelitis (CNO) has been identified as a disease entity for almost 50 years. This inflammatory bone disorder is characterized by osteolytic as well as hyperostotic/osteosclerotic lesions. It is chronic in nature, but it can present with episodic flairs and phases of remission, which have led to the denomination “chronic recurrent osteomyelitis”, with its severe multifocal form “chronic recurrent multifocal osteomyelitis” (CRMO). For almost three decades, an infectious aetiology had been considered, since especially Propionibacterium acnes had been isolated from bone lesions of individual patients. However, this concept has been challenged since long-term antibiotic therapy did not alter the course of disease and modern microbiological techniques (including PCR) failed to confirm bone infection as an underlying cause. Over recent years, a profound dysregulation of cytokine expression profiles has been demonstrated in innate immune cells of CNO patients. A hallmark of monocytes from CNO patients is the failure to produce immune regulatory cytokines interleukin-10 (IL-10) and IL-19, which have been linked with genetic and epigenetic alterations. Subsequently, a significant upregulation of pro-inflammatory, NLRP3 inflammasome-dependent cytokines (IL-1β and TNF-α), has been demonstrated. Summary The current knowledge on CNO, the underlying molecular pathophysiology, and modern imaging strategies are summarized; differential diagnoses, treatment options, outcome measures, as well as quality of life studies are discussed.

show abstract

Section: Treatment Monitoring and Treat-to-target Protocolsmentioning

confidence: 99%

New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO

Hedrich

Morbach

Reiser³

et al. 2020

Curr Rheumatol Rep

View full text Add to dashboard Cite

show abstract

“…Glucocorticosteroids play a relatively insignificant role, similarly to other spondyloarthropathies. Their application is limited to local or oral administration in acute presentations of the disease [17]. In recent years there have been some publications discussing the positive effects of SAPHO syndrome therapy with anti-TNF-alpha agents [18,19].…”

Section: Discussionmentioning

confidence: 99%

The evolving clinical picture of seronegative spondyloarthropathy based on the example of ankylosing spondylitis in a patient with primary diagnosis of the SAPHO syndrome – case presentation

Guzera¹,

Koasakowski²,

Jeka

2018

Medical Research Journal

View full text Add to dashboard Cite

Seronegative spondyloarthropathies are a group of diseases characterized by several clinical features such as inflammatory back pain, sacroiliac joint inflammation, and the presence of the HLA B27 antigen, which occurs more frequently than the general population. Non-specific bowel inflammation, skin lesions, particularly psoriasis or uveitis, are also typical in patients or their family members [1]. In many situations, clinical progression of spondyloarthropathies can be assessed by imaging of the sacroiliac joints [2, 3]. SAPHO syndrome (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis), is a rare disease, classified as seronegative spondyloarthropathy due to many typical clinical features for this group of diseases. A large variety of symptoms and atypical clinical picture of SAPHO syndrome causes significant diagnostic difficulties [3, 4]. Presented here is a case report of a 41-year-old male patient with a twenty-year history of the disease. Initially, his disease took the form of chronic, recurrent multifocal osteomyelitis (CRMO), which finally turned into a spondyloarthropathy that met the classification criteria for ankylosing spondylitis.

show abstract

“…This treatment was also associated with a significant reduction in bone marrow edema in vertebrae and sacroiliac joints seen on magnetic resonance imaging (MRI) 8 . However, BPs were proven ineffective in treating skin lesions 29,31 …”

Section: Pharmacological Optionsmentioning

confidence: 99%

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Slouma

Bettaieb²,

Rahmouni³

et al. 2021

J Clin Rheumatol

View full text Add to dashboard Cite

Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic disease with marked clinical and radiological heterogeneity. It is characterized by a combination of dermatological and osteoarticular manifestations. The treatment of SAPHO syndrome is not yet codified. It includes several therapeutic options such as anti-inflammatory drugs, bisphosphonates, antibiotics, conventional disease-modifying antirheumatic drugs, and biological treatment.This article aims to provide an updated review of the different pharmacological options for SAPHO syndrome. We also propose a therapeutic algorithm for the management of this disease.

show abstract

SAPHO syndrome treatment with intravenous pamidronate. Retrospective study of 22 patients

Cited by 25 publications

References 5 publications

New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO

New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO

The evolving clinical picture of seronegative spondyloarthropathy based on the example of ankylosing spondylitis in a patient with primary diagnosis of the SAPHO syndrome – case presentation

Pharmacological Management of Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome Syndrome

Contact Info

Product

Resources

About